In an interview with PharmaShots, Kathryn Lang, Vice President, Outcomes & Evidence at Guardant Health shared her views on the data from the VALUE study of Guardant360 liquid biopsy test for NSCLC
Shots:
The VALUE study evaluates the clinical outcomes & utility of liquid biopsy vs tissue biopsy testing in patients with NSCLC across six Canadian centers
In an initial diagnosis, patients treated…
